| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dry Eye Syndromes | 81 | 2025 | 247 | 18.230 |
Why?
|
| Lacrimal Apparatus | 30 | 2024 | 121 | 11.330 |
Why?
|
| Sjogren's Syndrome | 25 | 2024 | 84 | 9.750 |
Why?
|
| Epithelium, Corneal | 36 | 2025 | 172 | 7.570 |
Why?
|
| Conjunctiva | 44 | 2024 | 193 | 7.050 |
Why?
|
| Cornea | 39 | 2024 | 645 | 6.030 |
Why?
|
| Aging | 20 | 2024 | 1176 | 5.310 |
Why?
|
| Goblet Cells | 28 | 2024 | 103 | 5.020 |
Why?
|
| Mice, Inbred C57BL | 74 | 2025 | 4355 | 4.130 |
Why?
|
| Keratoconjunctivitis Sicca | 13 | 2023 | 42 | 3.960 |
Why?
|
| Interferon-gamma | 20 | 2022 | 500 | 3.730 |
Why?
|
| Tears | 29 | 2024 | 147 | 3.670 |
Why?
|
| Disease Models, Animal | 50 | 2025 | 4285 | 3.330 |
Why?
|
| Dacryocystitis | 5 | 2023 | 20 | 2.650 |
Why?
|
| Th1 Cells | 9 | 2024 | 152 | 2.620 |
Why?
|
| Burns, Chemical | 5 | 2017 | 29 | 2.570 |
Why?
|
| Mice | 101 | 2025 | 17540 | 2.550 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 7 | 2024 | 44 | 2.410 |
Why?
|
| Eye Burns | 5 | 2017 | 15 | 2.240 |
Why?
|
| Animals | 113 | 2025 | 33796 | 2.140 |
Why?
|
| Mice, Knockout | 34 | 2024 | 3722 | 2.130 |
Why?
|
| Th17 Cells | 7 | 2024 | 90 | 2.080 |
Why?
|
| Eye | 11 | 2022 | 227 | 2.060 |
Why?
|
| Cathepsins | 3 | 2024 | 21 | 1.760 |
Why?
|
| Inflammation | 20 | 2023 | 1403 | 1.720 |
Why?
|
| Cytokines | 23 | 2024 | 1284 | 1.700 |
Why?
|
| Wound Healing | 5 | 2024 | 451 | 1.570 |
Why?
|
| Dendritic Cells | 13 | 2024 | 403 | 1.420 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2016 | 280 | 1.350 |
Why?
|
| Butyrates | 2 | 2022 | 34 | 1.340 |
Why?
|
| Antigen-Presenting Cells | 3 | 2019 | 117 | 1.300 |
Why?
|
| Dexamethasone | 5 | 2016 | 271 | 1.280 |
Why?
|
| Stress, Physiological | 11 | 2016 | 258 | 1.270 |
Why?
|
| Flow Cytometry | 9 | 2024 | 803 | 1.260 |
Why?
|
| Eye Diseases | 2 | 2021 | 113 | 1.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2024 | 472 | 1.180 |
Why?
|
| Transcriptome | 4 | 2024 | 903 | 1.160 |
Why?
|
| Interleukin-13 | 4 | 2022 | 96 | 1.140 |
Why?
|
| Lipopolysaccharides | 4 | 2023 | 292 | 1.120 |
Why?
|
| Phenylalanine | 2 | 2018 | 120 | 1.090 |
Why?
|
| Adoptive Transfer | 13 | 2024 | 237 | 1.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 14 | 2025 | 510 | 1.050 |
Why?
|
| Cyclosporine | 5 | 2020 | 146 | 1.030 |
Why?
|
| Gene Expression Regulation | 15 | 2024 | 2524 | 1.010 |
Why?
|
| Female | 81 | 2025 | 65482 | 1.000 |
Why?
|
| Xerophthalmia | 3 | 2014 | 7 | 0.970 |
Why?
|
| Desiccation | 15 | 2024 | 43 | 0.960 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2022 | 680 | 0.960 |
Why?
|
| Oxidative Stress | 4 | 2020 | 795 | 0.950 |
Why?
|
| Interleukin-17 | 7 | 2016 | 118 | 0.940 |
Why?
|
| Microbiota | 3 | 2019 | 391 | 0.940 |
Why?
|
| RNA | 5 | 2016 | 569 | 0.940 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2022 | 116 | 0.930 |
Why?
|
| Matrix Metalloproteinase 9 | 7 | 2015 | 137 | 0.920 |
Why?
|
| Ophthalmic Solutions | 8 | 2022 | 89 | 0.890 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 771 | 0.880 |
Why?
|
| Keratoconjunctivitis | 3 | 2021 | 20 | 0.870 |
Why?
|
| Nerve Growth Factor | 1 | 2022 | 24 | 0.830 |
Why?
|
| Th2 Cells | 6 | 2023 | 187 | 0.820 |
Why?
|
| Immunity, Innate | 8 | 2022 | 372 | 0.810 |
Why?
|
| Cells, Cultured | 21 | 2022 | 3040 | 0.810 |
Why?
|
| Eye Injuries | 1 | 2022 | 48 | 0.800 |
Why?
|
| Lubricant Eye Drops | 2 | 2019 | 8 | 0.790 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 133 | 0.790 |
Why?
|
| Corneal Injuries | 2 | 2024 | 28 | 0.780 |
Why?
|
| Homeodomain Proteins | 4 | 2018 | 544 | 0.780 |
Why?
|
| Germ-Free Life | 2 | 2018 | 59 | 0.740 |
Why?
|
| Immune Tolerance | 5 | 2021 | 145 | 0.740 |
Why?
|
| Dysbiosis | 2 | 2019 | 118 | 0.730 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 2 | 2011 | 14 | 0.730 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 91 | 0.710 |
Why?
|
| RNA, Messenger | 16 | 2018 | 2809 | 0.710 |
Why?
|
| Nerve Tissue | 1 | 2020 | 6 | 0.710 |
Why?
|
| Microscopy, Confocal | 14 | 2024 | 348 | 0.700 |
Why?
|
| Inflammasomes | 4 | 2023 | 150 | 0.700 |
Why?
|
| Doxycycline | 4 | 2016 | 115 | 0.700 |
Why?
|
| Parity | 1 | 2020 | 78 | 0.700 |
Why?
|
| Axons | 2 | 2020 | 380 | 0.690 |
Why?
|
| Cell Proliferation | 6 | 2020 | 2307 | 0.680 |
Why?
|
| Alkalies | 5 | 2017 | 24 | 0.660 |
Why?
|
| Interferon Type I | 1 | 2020 | 107 | 0.650 |
Why?
|
| Killer Cells, Natural | 2 | 2012 | 320 | 0.650 |
Why?
|
| Epithelial Cells | 14 | 2023 | 899 | 0.640 |
Why?
|
| Conjunctivitis, Allergic | 5 | 2020 | 15 | 0.640 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 216 | 0.640 |
Why?
|
| Eye Proteins | 4 | 2018 | 217 | 0.630 |
Why?
|
| T-Lymphocytes | 8 | 2017 | 1691 | 0.620 |
Why?
|
| Autoimmune Diseases | 2 | 2011 | 250 | 0.620 |
Why?
|
| Membrane Proteins | 9 | 2017 | 1522 | 0.610 |
Why?
|
| Sulfones | 1 | 2018 | 66 | 0.610 |
Why?
|
| Ophthalmic Nerve | 1 | 2018 | 5 | 0.600 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2023 | 111 | 0.600 |
Why?
|
| Symbiosis | 1 | 2018 | 65 | 0.600 |
Why?
|
| Meibomian Glands | 6 | 2022 | 28 | 0.590 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 26 | 0.580 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 143 | 0.580 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 13 | 2018 | 105 | 0.580 |
Why?
|
| Humans | 66 | 2023 | 123046 | 0.540 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2014 | 393 | 0.540 |
Why?
|
| Autoimmunity | 3 | 2017 | 172 | 0.530 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2016 | 15 | 0.530 |
Why?
|
| Methylprednisolone | 2 | 2006 | 90 | 0.520 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 50 | 0.520 |
Why?
|
| Corneal Diseases | 2 | 2009 | 101 | 0.520 |
Why?
|
| Epithelium | 4 | 2023 | 362 | 0.510 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 16 | 0.510 |
Why?
|
| Interleukin-1 | 3 | 2025 | 143 | 0.490 |
Why?
|
| Thrombospondin 1 | 2 | 2023 | 22 | 0.490 |
Why?
|
| Male | 41 | 2024 | 60089 | 0.480 |
Why?
|
| Signal Transduction | 11 | 2022 | 4493 | 0.480 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 19 | 0.480 |
Why?
|
| Protein Precursors | 9 | 2011 | 149 | 0.480 |
Why?
|
| Cell Count | 9 | 2020 | 250 | 0.470 |
Why?
|
| Permeability | 6 | 2018 | 118 | 0.460 |
Why?
|
| Biomarkers | 10 | 2019 | 2943 | 0.450 |
Why?
|
| Receptors, CCR6 | 1 | 2013 | 6 | 0.450 |
Why?
|
| Piperidines | 1 | 2015 | 200 | 0.450 |
Why?
|
| Receptors, CXCR3 | 1 | 2013 | 20 | 0.450 |
Why?
|
| Limbus Corneae | 5 | 2007 | 33 | 0.440 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2019 | 195 | 0.430 |
Why?
|
| Macrophages | 6 | 2024 | 605 | 0.420 |
Why?
|
| Glucocorticoids | 3 | 2016 | 377 | 0.420 |
Why?
|
| Phenotype | 9 | 2023 | 4226 | 0.420 |
Why?
|
| Corneal Topography | 3 | 2009 | 192 | 0.410 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 1688 | 0.410 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 455 | 0.410 |
Why?
|
| Blotting, Western | 8 | 2024 | 1100 | 0.410 |
Why?
|
| Prodrugs | 1 | 2012 | 59 | 0.410 |
Why?
|
| Lymphoid Tissue | 2 | 2023 | 45 | 0.410 |
Why?
|
| Apoptosis | 7 | 2013 | 1782 | 0.400 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 15 | 2012 | 1290 | 0.400 |
Why?
|
| Mucous Membrane | 3 | 2022 | 84 | 0.400 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2012 | 79 | 0.390 |
Why?
|
| Occludin | 4 | 2021 | 18 | 0.380 |
Why?
|
| Organic Chemicals | 4 | 2015 | 59 | 0.380 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 6 | 2011 | 19 | 0.360 |
Why?
|
| Mucin 5AC | 5 | 2020 | 24 | 0.360 |
Why?
|
| Cell Movement | 6 | 2016 | 831 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2023 | 665 | 0.340 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2010 | 77 | 0.330 |
Why?
|
| Interleukin-12 | 3 | 2018 | 113 | 0.330 |
Why?
|
| Fluorescein | 5 | 2023 | 37 | 0.330 |
Why?
|
| Drug Delivery Systems | 3 | 2021 | 182 | 0.330 |
Why?
|
| B7-2 Antigen | 2 | 2019 | 16 | 0.330 |
Why?
|
| Cell Size | 2 | 2008 | 81 | 0.320 |
Why?
|
| ATP-Binding Cassette Transporters | 5 | 2008 | 186 | 0.320 |
Why?
|
| Lipid Metabolism | 5 | 2024 | 349 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 3 | 2017 | 64 | 0.320 |
Why?
|
| Homeostasis | 2 | 2021 | 683 | 0.300 |
Why?
|
| Stem Cells | 8 | 2023 | 701 | 0.290 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2018 | 93 | 0.290 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2022 | 13 | 0.280 |
Why?
|
| Administration, Topical | 4 | 2015 | 141 | 0.280 |
Why?
|
| Cell Differentiation | 8 | 2018 | 1909 | 0.280 |
Why?
|
| Keratomileusis, Laser In Situ | 2 | 2006 | 148 | 0.280 |
Why?
|
| Chemokine CXCL11 | 2 | 2018 | 7 | 0.280 |
Why?
|
| Chemokine CXCL9 | 2 | 2018 | 14 | 0.270 |
Why?
|
| Mice, Inbred NOD | 5 | 2023 | 285 | 0.270 |
Why?
|
| Aged | 18 | 2022 | 19083 | 0.270 |
Why?
|
| Lymphocyte Activation | 4 | 2019 | 684 | 0.270 |
Why?
|
| Neoplasm Proteins | 5 | 2008 | 668 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2015 | 810 | 0.260 |
Why?
|
| B-Lymphocytes | 2 | 2023 | 518 | 0.250 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 110 | 0.250 |
Why?
|
| Chemokine CXCL10 | 2 | 2016 | 52 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 2845 | 0.250 |
Why?
|
| Interleukin-1beta | 4 | 2023 | 159 | 0.250 |
Why?
|
| Tight Junction Proteins | 2 | 2021 | 12 | 0.240 |
Why?
|
| Chemokine CCL20 | 2 | 2016 | 16 | 0.240 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2018 | 458 | 0.240 |
Why?
|
| Middle Aged | 22 | 2022 | 25972 | 0.230 |
Why?
|
| Re-Epithelialization | 1 | 2024 | 11 | 0.230 |
Why?
|
| Hyperesthesia | 1 | 2004 | 2 | 0.230 |
Why?
|
| Fluorophotometry | 4 | 2009 | 30 | 0.230 |
Why?
|
| Adult | 22 | 2021 | 28972 | 0.230 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2024 | 65 | 0.230 |
Why?
|
| Myopia | 1 | 2006 | 193 | 0.220 |
Why?
|
| Air | 1 | 2004 | 26 | 0.220 |
Why?
|
| Debridement | 1 | 2024 | 84 | 0.220 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 170 | 0.220 |
Why?
|
| Parabiosis | 1 | 2023 | 3 | 0.210 |
Why?
|
| Receptor, trkC | 1 | 2022 | 4 | 0.210 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2016 | 18 | 0.210 |
Why?
|
| Receptor, trkB | 1 | 2022 | 20 | 0.210 |
Why?
|
| Receptor, trkA | 1 | 2022 | 16 | 0.210 |
Why?
|
| Mitomycin | 1 | 2022 | 49 | 0.210 |
Why?
|
| Interleukin-2 | 1 | 2023 | 224 | 0.210 |
Why?
|
| Ligands | 2 | 2022 | 533 | 0.200 |
Why?
|
| Cholinergic Antagonists | 3 | 2013 | 51 | 0.200 |
Why?
|
| Paracrine Communication | 1 | 2022 | 71 | 0.200 |
Why?
|
| Mice, Inbred BALB C | 7 | 2020 | 1002 | 0.200 |
Why?
|
| Monocytes | 2 | 2022 | 345 | 0.200 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2020 | 16 | 0.200 |
Why?
|
| Polysaccharides, Bacterial | 4 | 2014 | 67 | 0.200 |
Why?
|
| Keratoconus | 1 | 2003 | 60 | 0.200 |
Why?
|
| Bone Marrow Cells | 4 | 2018 | 260 | 0.200 |
Why?
|
| Fatty Acids, Volatile | 1 | 2022 | 33 | 0.200 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2022 | 32 | 0.200 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2021 | 16 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 375 | 0.200 |
Why?
|
| Tretinoin | 2 | 2021 | 116 | 0.190 |
Why?
|
| Forkhead Transcription Factors | 4 | 2020 | 367 | 0.190 |
Why?
|
| Immune System | 2 | 2021 | 87 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 267 | 0.190 |
Why?
|
| Sex Characteristics | 1 | 2023 | 312 | 0.190 |
Why?
|
| Biological Transport | 2 | 2012 | 347 | 0.190 |
Why?
|
| Immune Privilege | 1 | 2021 | 2 | 0.190 |
Why?
|
| Case-Control Studies | 4 | 2020 | 3233 | 0.190 |
Why?
|
| Glaucoma | 1 | 2022 | 89 | 0.190 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2020 | 9 | 0.180 |
Why?
|
| Retinoids | 1 | 2021 | 33 | 0.180 |
Why?
|
| Thiones | 1 | 2020 | 9 | 0.180 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2012 | 16 | 0.180 |
Why?
|
| Mucins | 3 | 2017 | 74 | 0.180 |
Why?
|
| Spleen | 1 | 2021 | 272 | 0.180 |
Why?
|
| Receptors, Interleukin-9 | 1 | 2020 | 2 | 0.180 |
Why?
|
| Interleukin-9 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Interleukin-33 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Thiophenes | 1 | 2020 | 60 | 0.180 |
Why?
|
| Pyrazines | 1 | 2020 | 73 | 0.170 |
Why?
|
| Calcineurin Inhibitors | 1 | 2020 | 28 | 0.170 |
Why?
|
| Chemokines | 3 | 2010 | 136 | 0.170 |
Why?
|
| Fluorescent Dyes | 2 | 2012 | 260 | 0.170 |
Why?
|
| Receptors, Chemokine | 2 | 2011 | 43 | 0.170 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 102 | 0.170 |
Why?
|
| Immunophenotyping | 2 | 2018 | 328 | 0.170 |
Why?
|
| Transforming Growth Factor beta2 | 2 | 2010 | 8 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 254 | 0.160 |
Why?
|
| Autoantibodies | 2 | 2012 | 424 | 0.160 |
Why?
|
| Interleukin-27 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Lysosomal-Associated Membrane Protein 3 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2018 | 18 | 0.160 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2018 | 10 | 0.160 |
Why?
|
| Beclin-1 | 1 | 2018 | 26 | 0.160 |
Why?
|
| Nanostructures | 2 | 2016 | 52 | 0.160 |
Why?
|
| Humidity | 3 | 2015 | 23 | 0.160 |
Why?
|
| Transglutaminases | 3 | 2006 | 24 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 413 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2019 | 162 | 0.140 |
Why?
|
| Colony-Forming Units Assay | 3 | 2008 | 69 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 353 | 0.140 |
Why?
|
| Caspase 8 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Epidermal Growth Factor | 3 | 2012 | 122 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 296 | 0.140 |
Why?
|
| Flagellin | 2 | 2014 | 19 | 0.140 |
Why?
|
| Caspase 1 | 1 | 2017 | 41 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 43 | 0.140 |
Why?
|
| Dehydration | 2 | 2007 | 37 | 0.140 |
Why?
|
| Antibodies | 2 | 2017 | 371 | 0.140 |
Why?
|
| Time Factors | 3 | 2013 | 6218 | 0.130 |
Why?
|
| Mice, Nude | 3 | 2012 | 694 | 0.130 |
Why?
|
| Cell Adhesion | 2 | 2015 | 318 | 0.130 |
Why?
|
| Tongue | 1 | 2016 | 29 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 151 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 4 | 2010 | 260 | 0.130 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 62 | 0.130 |
Why?
|
| Blinking | 3 | 2015 | 27 | 0.130 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 65 | 0.130 |
Why?
|
| Integrin alpha4 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Integrin alpha4beta1 | 1 | 2015 | 17 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 211 | 0.130 |
Why?
|
| Sensation | 2 | 2007 | 58 | 0.130 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2015 | 12 | 0.130 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 63 | 0.120 |
Why?
|
| Environment, Controlled | 1 | 2015 | 7 | 0.120 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 642 | 0.120 |
Why?
|
| NIH 3T3 Cells | 2 | 2005 | 92 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2022 | 6371 | 0.120 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 4 | 0.120 |
Why?
|
| Conjunctival Diseases | 1 | 2015 | 31 | 0.120 |
Why?
|
| Antigens, Ly | 1 | 2014 | 32 | 0.120 |
Why?
|
| Acute Disease | 1 | 2018 | 1093 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1071 | 0.120 |
Why?
|
| OX40 Ligand | 2 | 2011 | 8 | 0.120 |
Why?
|
| Cell Survival | 3 | 2012 | 808 | 0.120 |
Why?
|
| Cell Membrane Permeability | 2 | 2012 | 73 | 0.120 |
Why?
|
| Autoantigens | 2 | 2012 | 119 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2018 | 676 | 0.120 |
Why?
|
| Bromodeoxyuridine | 4 | 2010 | 60 | 0.120 |
Why?
|
| Leukocytes | 1 | 2015 | 206 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2013 | 376 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3011 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 233 | 0.110 |
Why?
|
| Neutrophils | 1 | 2016 | 373 | 0.110 |
Why?
|
| Choline | 1 | 1994 | 54 | 0.110 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 2395 | 0.110 |
Why?
|
| Models, Animal | 3 | 2017 | 464 | 0.110 |
Why?
|
| Lymphocyte Depletion | 1 | 2013 | 124 | 0.110 |
Why?
|
| Phospholipids | 1 | 1994 | 107 | 0.110 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2004 | 97 | 0.110 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 126 | 0.100 |
Why?
|
| Decidua | 1 | 1994 | 136 | 0.100 |
Why?
|
| Cytoplasm | 1 | 1994 | 288 | 0.100 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 98 | 0.100 |
Why?
|
| Feces | 1 | 2016 | 710 | 0.100 |
Why?
|
| Tissue Kallikreins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Visual Acuity | 4 | 2009 | 808 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2012 | 421 | 0.100 |
Why?
|
| Corneal Stroma | 1 | 2012 | 90 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2017 | 516 | 0.100 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 2 | 2008 | 22 | 0.100 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2011 | 24 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2011 | 63 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2014 | 792 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 107 | 0.090 |
Why?
|
| Genes, Dominant | 1 | 2011 | 251 | 0.090 |
Why?
|
| Bacterial Capsules | 3 | 2005 | 37 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2012 | 176 | 0.090 |
Why?
|
| STAT6 Transcription Factor | 1 | 2010 | 36 | 0.090 |
Why?
|
| Gene Expression | 2 | 2012 | 1565 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 827 | 0.090 |
Why?
|
| Nasolacrimal Duct | 1 | 2010 | 22 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2009 | 27 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Pregnancy | 2 | 2020 | 7137 | 0.080 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2009 | 4 | 0.080 |
Why?
|
| Interleukin-18 | 2 | 2023 | 60 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 2 | 2006 | 27 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 2028 | 0.080 |
Why?
|
| Biomedical Engineering | 1 | 2008 | 30 | 0.080 |
Why?
|
| Tetracycline | 1 | 2008 | 78 | 0.080 |
Why?
|
| Cell Communication | 2 | 2020 | 165 | 0.080 |
Why?
|
| Risk Factors | 2 | 2017 | 10009 | 0.080 |
Why?
|
| Interleukins | 2 | 2025 | 118 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 66 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 3661 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 1386 | 0.070 |
Why?
|
| Young Adult | 5 | 2017 | 8832 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 256 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2007 | 13 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2008 | 147 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2007 | 72 | 0.070 |
Why?
|
| Blepharoplasty | 1 | 2007 | 22 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2008 | 287 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2018 | 55 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 459 | 0.070 |
Why?
|
| Eyelids | 1 | 2007 | 115 | 0.070 |
Why?
|
| Depression, Chemical | 1 | 2006 | 43 | 0.070 |
Why?
|
| NF-kappa B | 2 | 2023 | 457 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 317 | 0.070 |
Why?
|
| Metaplasia | 1 | 2007 | 215 | 0.070 |
Why?
|
| Staining and Labeling | 3 | 2013 | 183 | 0.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 91 | 0.060 |
Why?
|
| Chemokine CCL5 | 2 | 2021 | 54 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 171 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2011 | 123 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 130 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2015 | 6027 | 0.060 |
Why?
|
| Collagen Type IV | 1 | 2005 | 20 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 1339 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 206 | 0.060 |
Why?
|
| Caspases | 3 | 2011 | 159 | 0.060 |
Why?
|
| Tight Junctions | 1 | 2025 | 39 | 0.060 |
Why?
|
| Phagocytes | 1 | 2024 | 24 | 0.060 |
Why?
|
| Clone Cells | 1 | 2005 | 163 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2004 | 26 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2393 | 0.060 |
Why?
|
| Androstadienes | 1 | 2004 | 49 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 315 | 0.060 |
Why?
|
| Mechanoreceptors | 1 | 2004 | 11 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2006 | 206 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2009 | 2585 | 0.050 |
Why?
|
| Nigericin | 1 | 2023 | 2 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2003 | 118 | 0.050 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2003 | 48 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2023 | 89 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2022 | 56 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 180 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 555 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2021 | 61 | 0.050 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2021 | 6 | 0.050 |
Why?
|
| Cell Division | 3 | 2010 | 780 | 0.050 |
Why?
|
| Vitamin A Deficiency | 1 | 2021 | 13 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 376 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2004 | 16043 | 0.050 |
Why?
|
| Astigmatism | 1 | 2003 | 176 | 0.050 |
Why?
|
| Corneal Transplantation | 2 | 2012 | 48 | 0.050 |
Why?
|
| CD4 Antigens | 1 | 2020 | 56 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 202 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2021 | 100 | 0.050 |
Why?
|
| Cell Separation | 2 | 2011 | 231 | 0.040 |
Why?
|
| Vitamin A | 1 | 2021 | 59 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2020 | 90 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 98 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 402 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 5038 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 1439 | 0.040 |
Why?
|
| Benzalkonium Compounds | 1 | 2019 | 3 | 0.040 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2019 | 14 | 0.040 |
Why?
|
| Blood | 1 | 2000 | 105 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3867 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 220 | 0.040 |
Why?
|
| Chromans | 1 | 2018 | 5 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 607 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2020 | 340 | 0.040 |
Why?
|
| Benzoates | 1 | 2018 | 20 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3039 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 880 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2011 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 101 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1584 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2005 | 467 | 0.040 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2017 | 13 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2017 | 318 | 0.030 |
Why?
|
| Adolescent | 4 | 2017 | 19075 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 543 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 312 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 2006 | 203 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2015 | 75 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1236 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 217 | 0.030 |
Why?
|
| Integrin beta1 | 2 | 2005 | 54 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 235 | 0.030 |
Why?
|
| Connexin 43 | 2 | 2004 | 30 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 310 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 481 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1994 | 99 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2005 | 202 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 330 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 512 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2014 | 84 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2013 | 24 | 0.030 |
Why?
|
| Lissamine Green Dyes | 1 | 2013 | 7 | 0.030 |
Why?
|
| Eye Protective Devices | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 311 | 0.030 |
Why?
|
| Cell Line | 2 | 2010 | 2771 | 0.030 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 27 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 32 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 54 | 0.030 |
Why?
|
| Phosphoproteins | 2 | 2005 | 399 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 69 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2013 | 61 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1923 | 0.030 |
Why?
|
| Complement C3b | 1 | 2012 | 7 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 294 | 0.030 |
Why?
|
| Kallikreins | 1 | 2012 | 26 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 83 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 253 | 0.020 |
Why?
|
| Complement Activation | 1 | 2012 | 52 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 176 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2012 | 118 | 0.020 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 2055 | 0.020 |
Why?
|
| Ambrosia | 1 | 2011 | 14 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2011 | 25 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 69 | 0.020 |
Why?
|
| fas Receptor | 1 | 2011 | 41 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 87 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 37 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 126 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2011 | 238 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2011 | 84 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2005 | 809 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 167 | 0.020 |
Why?
|
| Receptors, OX40 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 12 | 0.020 |
Why?
|
| Osmosis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Poly I-C | 1 | 2010 | 23 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2010 | 32 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2010 | 58 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 100 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2010 | 78 | 0.020 |
Why?
|
| Pollen | 1 | 2010 | 45 | 0.020 |
Why?
|
| Plant Proteins | 1 | 2010 | 74 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 233 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2010 | 169 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 769 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2008 | 2 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2008 | 11 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2799 | 0.020 |
Why?
|
| Eyelid Diseases | 1 | 2008 | 67 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2008 | 129 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2008 | 40 | 0.020 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2007 | 5 | 0.020 |
Why?
|
| Emulsions | 1 | 2008 | 65 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 256 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2008 | 256 | 0.020 |
Why?
|
| Allergens | 1 | 2010 | 248 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 412 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 290 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 747 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 393 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2007 | 382 | 0.020 |
Why?
|
| Blepharoptosis | 1 | 2007 | 67 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 30 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 22 | 0.020 |
Why?
|
| Cadaverine | 1 | 2006 | 4 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 330 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2006 | 131 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 555 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 1017 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 966 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 608 | 0.020 |
Why?
|
| Keratin-12 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Keratins | 1 | 2005 | 55 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 1268 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 1588 | 0.020 |
Why?
|
| Loteprednol Etabonate | 1 | 2004 | 5 | 0.010 |
Why?
|
| Suspensions | 1 | 2004 | 9 | 0.010 |
Why?
|
| Tonometry, Ocular | 1 | 2004 | 31 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 940 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 664 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 1068 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 2004 | 10 | 0.010 |
Why?
|
| Nestin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2008 | 678 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2004 | 29 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 119 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 660 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 218 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 697 | 0.010 |
Why?
|
| Integrins | 1 | 2004 | 82 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1162 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 570 | 0.010 |
Why?
|
| Cadherins | 1 | 2004 | 164 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2004 | 284 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 1463 | 0.010 |
Why?
|
| Swine | 1 | 2006 | 1155 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1583 | 0.010 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2000 | 11 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 1389 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2006 | 13888 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1112 | 0.010 |
Why?
|
| Child | 2 | 2006 | 24221 | 0.010 |
Why?
|